Nesfatin-1 and other hormone alterations in polycystic ovary syndrome
- PMID: 22367584
- DOI: 10.1007/s12020-012-9638-7
Nesfatin-1 and other hormone alterations in polycystic ovary syndrome
Abstract
Polycystic ovary syndrome (PCOS) is commonly characterised by obesity, insulin resistance (IR), hyperandrogenemia and hirsutism. Nesfatin-1 a recently discovered hormone, acts upon energy balance, glucose metabolism, obesity and probably gonadal functions. This study was to evaluate the circulating levels of nesfatin-1 in patients with PCOS (n = 30) and in age and body mass index (BMI)-matched controls (n = 30). PCOS patients had significantly lower levels of nesfatin-1 (0.88 ± 0.36 ng/mL) than healthy controls (2.22 ± 1.14 ng/mL). PCOS patients also had higher gonadotropin and androgen plasma concentrations, Ferriman-Gallwey scores, blood glucose levels and a homeostasis model of assessment-IR index (HOMA-IR) index than in healthy women. Correlation tests in PCOS subjects detected a negative correlation between nesfatin-1 levels and BMI, fasting blood glucose, insulin levels and a HOMA-IR index. Lower nesfatin-1 concentration may plays a very important role in the development of PCOS.
Similar articles
-
Plasma nesfatin-1 levels are increased in patients with polycystic ovary syndrome.J Endocrinol Invest. 2014 Aug;37(8):715-719. doi: 10.1007/s40618-014-0089-2. Epub 2014 Jun 12. J Endocrinol Invest. 2014. PMID: 24920281
-
The role of nesfatin-1 expression in letrozole-induced polycystic ovaries in the rat.Gynecol Endocrinol. 2017 Jun;33(6):438-441. doi: 10.1080/09513590.2017.1290068. Epub 2017 Feb 21. Gynecol Endocrinol. 2017. PMID: 28277136
-
Nesfatin-1 and Vitamin D levels may be associated with systolic and diastolic blood pressure values and hearth rate in polycystic ovary syndrome.Bosn J Basic Med Sci. 2015 Jul 9;15(3):57-63. doi: 10.17305/bjbms.2015.432. Bosn J Basic Med Sci. 2015. PMID: 26295295 Free PMC article.
-
Nucleobindin-2 derived nesfatin-1 in polycystic ovary syndrome: a PRISMA and GRADE-compliant systematic review and meta-analysis with diagnostic test accuracy.Minerva Endocrinol (Torino). 2024 Mar;49(1):111-121. doi: 10.23736/S2724-6507.23.04003-4. Epub 2023 Nov 9. Minerva Endocrinol (Torino). 2024. PMID: 37943280
-
Blood nesfatin-1 levels in patients with polycystic ovary syndrome: a systematic review and meta-analysis.Front Endocrinol (Lausanne). 2024 Jan 24;14:1275753. doi: 10.3389/fendo.2023.1275753. eCollection 2023. Front Endocrinol (Lausanne). 2024. PMID: 38327900 Free PMC article.
Cited by
-
DLK1 and Nesfatin-1 levels and the relationship with metabolic parameters in polycystic ovary syndrome: Prospective, controlled study.Turk J Obstet Gynecol. 2021 Jun 2;18(2):124-130. doi: 10.4274/tjod.galenos.2021.39024. Turk J Obstet Gynecol. 2021. PMID: 34083652 Free PMC article.
-
Multi-functional peptide hormone NUCB2/nesfatin-1.Endocrine. 2013 Oct;44(2):312-25. doi: 10.1007/s12020-013-9923-0. Epub 2013 Mar 23. Endocrine. 2013. PMID: 23526235 Review.
-
Nesfatin-1 regulates the phenotype transition of cavernous smooth muscle cells by activating PI3K/AKT/mTOR signaling pathway to improve diabetic erectile dysfunction.PLoS One. 2024 Sep 3;19(9):e0304485. doi: 10.1371/journal.pone.0304485. eCollection 2024. PLoS One. 2024. Retraction in: PLoS One. 2024 Dec 2;19(12):e0314890. doi: 10.1371/journal.pone.0314890. PMID: 39226294 Free PMC article. Retracted.
-
Lifestyle intervention and anti-obesity therapies in the polycystic ovary syndrome: impact on metabolism and fertility.Endocrine. 2013 Dec;44(3):583-90. doi: 10.1007/s12020-013-9971-5. Epub 2013 Apr 27. Endocrine. 2013. PMID: 23625194 Review.
-
The Relationship between Nesfatin-1 Levels and SYNTAX Score in Patients with Non-ST Segment Elevation Myocardial Infarction.Acta Cardiol Sin. 2018 Sep;34(5):386-393. doi: 10.6515/ACS.201809_34(5).20180423A. Acta Cardiol Sin. 2018. PMID: 30271088 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical